JD Health Enhances O2O Effort for Parkinson’s Disease

by Vivian Yang

JD Health’s online pharmacy resources will be integrated into the mobile app of Shanghai Huashan Hospital for Parkinson’s disease to improve patients’ accessibility to medication and their overall treatment experience, which was announced on Feb 26 in Shanghai.

The medical platform for Parkinson’s disease is first of its kind in China to integrate online resources in the whole treatment process for Parkinson’s disease, with pharmaceutical services, covering pre-diagnosis, diagnosis and post-diagnosis healthcare management.  The project is the joint effort of JD Health, Huashan Hospital affiliated with Fudan University, and German pharmaceutical manufacturer Boehringer-Ingelheim.

The launch ceremony of the medical platform for Parkinson's disease 

The launch ceremony of the medical platform for Parkinson’s disease 

In the first stage, the project will be focused on the patient service model developed by Huashan Hospital, which has been a pioneer in the diagnosis and treatment of Parkinson’s disease in China for over 50 years, and began to build its online database platform for the disease’s management in 2011. The platform has evolved over the years into a mobile app known as Pawei(帕为), and an internet-based hub that pools multiple disciplines together in the areas of neurology, neurosurgery, rehabilitation, psychology and more to provide a one-stop service for patients with Parkinson’s disease.

Though patients can make doctor appointment easier through this platform and get the prescriptions, many patients said that they could not find certain medicines in their vicinity.

Under the agreement of this project, Pawei will feature a medicine supply section on its landing page which directs users to JD Health’s online care center for Parkinson’s disease where patients can order medication directly from JD Pharmacy. Patients can find almost all medication available on the Chinese market through this platform and enjoy JD’s same-day or next-day delivery service covering more than 90% of areas in the country.

Valuable knowledge and information about Parkinson’s currently available on Pawei will also be made available on JD Health to further promote and facilitate further education around the disease.

“With the development of telemedicine, managing chronic diseases via online channels has proven to be an effective way to save patients’ hospital visiting time,” noted Dr. Ying Mao, president of Huashan Hospital, at the center launch ceremony.

According to Mao, each year, nearly 12,000 Parkinson’s patients come to Huashan Hospital collectively making a total of 30,000 visits. More than half of the patients are from outside of Shanghai. “I make it so the simple and repetitive tasks can be processed online, such as revisiting doctors and dispensing medication, our limited offline hospital resources can be saved for patients who need them most,” Mao added.

It is estimated that there are about three million patients with Parkinson’s in China, , with a prevalence rate of 1.7% among people over 65 years old. The rate is going up with the aging of the Chinese population. According to the WHO’s estimate, the number of patients with Parkinson’s disease in China will reach 5 million by 2030.

 

(vivian.yang@jd.com)

 

 

JD Health Establishes Rare Diseases Care Center

by Vivian Yang

JD Health, the healthcare subsidiary of JD.com announced to establish the Rare Diseases Care Project on Feb 27, ahead of the upcoming World Rare Disease Day which will fall on the last day of February of the year.

JD Health’s Project will first focus on the building of a Rare Disease Care Center under JD Pharmacy and the establishment of a dedicated fund for patients with rare diseases, said Lijun Xin, CEO of JD Health at the launch ceremony of the center.

Lijun Xin, CEO of JD Health at the launch ceremony of the center.

Lijun Xin, CEO of JD Health

Launch ceremony of JD Health Disease Care Center

Launch ceremony of JD Health Disease Care Center

To tackle the issue of patients’ financial burdens, JD Health cooperated with the Illness Challenges Foundation, a Beijing-based advocacy NGO for rare diseases, to set up a fund to provide charity subsidies for patients.

“Rare Diseases are not only a worldwide medical challenge, but also an economic and social conundrum”, said Enlin Jin, general manager of the medical department of JD Health. Jin highlighted four features of the fund which are comprehensiveness – covering 121 rare diseases on the government-approved list, three-tiered financial aid – depending on the expenses of each disease treatment, multi-party participation – with the combination of JD’s own fund and its charity initiative together with merchants, and a whole process online – with application, review and fund granting steps all processed on the internet.

Enlin Jin (left) and Wang Yi’ou at the signing ceremony of the Rare Diseases Care Fund

Enlin Jin (left) and Wang Yi’ou at the signing ceremony of the Rare Diseases Care Fund

Customers who purchased eligible medicines on JD Pharmacy can submit their medical documents via JD’s online platforms for the Foundation’s review. The Foundation will assess the medical treatment and expenses of each case and allocate financial aid from JD Health’s fund to the patients. Each patient can receive up to RMB 50,000 yuan a year.

Wang Yi’ou, secretary general of Beijing Illness Challenges Foundation pointed out that the “1+N” multi-level payment system for the use of rare diseases drugs which is led by the government and supplemented by contributions from the market and society, has become a widely recognized approach to alleviate rare disease patients’ payment pressure.

“JD Health’s fund for rare diseases is a significant move to explore this joint payment model in an online format, ” said Wang. Wang, 39, with a height of 140 cm (4.5 feet), is a rare disease patient herself. She suffers from osteogenesis imperfect, a condition that causes extremely fragile bones, also known as “China doll” syndrome.

JD Health will continue to strengthen collaboration with partners from all relevant fields to enhance support for patients with rare diseases in China, covering their accessibility to specific drugs, quicker diagnosis and treatment, exploration of a multi-party medical payment system, and participation in society, added Xin.

Leveraging JD’s integrated online-to-offline supply chain solutions, JD Pharmacy, the medical product-selling platform of JD Health, is one of the most comprehensive pharmaceutical products providers in China. The company’s nationwide logistics network and temperature-controlled warehousing and transportation capacity ensure medicines’ secure and timely delivery to patients across the country.

Representatives from the World Health Organization (WHO), the Beijing Rare Diseases Treatment and Social Security Society, and pharmaceutical manufacturers including Novartis, Sanofi, Pfizer, BeiGene and CANbridge attended the center’s launch ceremony and shared their views on related issues with the audience.

Click here to read more about rare diseases in China and news about JD Health.

 

(vivian.yang@jd.com)

Posted in ESG

Jingxi Benefits Tens of Thousands of Farms

by Martin Li

Jingxi, JD’s social commerce platform, has covered tens of thousands of farms and helped farmers sell one million tons produce since the start of its operation in September 2019.

A total of 120,000 rural households have been making use of the online platform to sell their quality products to more consumers.

Zhang Yulin, a honey melon farmer in northwest China’s Gansu province, sold more than 6,000 kilograms of honey melons in the first week after his fruits went on sale on Jingxi last year. His income Increased exponentially.

“It was impossible in the past. I wouldn’t have dreamed of this,” said Zhang.

Minqin, the county where Zhang lives, has undesirable natural conditions. More than 90 percent of the county is covered by desert. However, the sharp temperature disparity between daytime and night is conducive to growing sweet honey melon.

Before the country government partnered with e-commerce players like JD, local farmers depended on middlemen to sell fruit, which meant farmers often sell their melon at very low price.

On July 27 last year, the county government signed a cooperation agreement with Jingxi to have the platform help local famers and businesses expand new market channels.

Jingxi has been cooperating with over 200 industry clusters around China to make use of its strengths in online traffic, supply chain and livestreaming to digitalize rural businesses.

Among the beneficiaries are orange farmers in Yichang, Hubei province. The pandemic took a toll on the fruit farmers—but after using the Jingxi platform, it took less than 20 days for one fruit store to fulfil over 40,000 orders.

 

(bjlihao3@jd.com)

In-Depth Report: Rare Diseases in China and the Mission of JD Health

by Vivian Yang

On Feb. 27, the day before World Rare Disease Day (last day of February each year since 2008), the Illness Challenge Foundation released An Observation Report on Rare Disease in China (referred to below as “the report”), providing an overview of the changes in rare diseases in China over the past decade. It analyzes and interprets changes in the community, policy, and industry from the patients’ perspective, and suggests the direction of future development of rare diseases in China.

The report is developed with the support of JD Health, the healthcare subsidiary of JD.com. The company provides the most comprehensive pharmaceutical products and the leading telemedicine services in China, including orphan drugs for patients with rare diseases. On the day the report was released, JD announced to join hands with the Illness Challenge Foundation to create a dedicated fund for rare disease patients in China.

“The world has kissed my soul with its pain, asking for its return in songs.” Wang Yi’ou, founder of the Illness Challenge Foundation, loves to quote this poem by Rabindranath Tagore, and jokingly refers it as the best “chicken soup” for patients with rare diseases.

In fact, Wang has had a band with her fellow patients with rare diseases since 2015. The band is called “8772” which is the transformation of BTTZ, the initial letters of the Chinese pronunciation of “illness challenges” (Bing Tong Tiao Zhan). The band writes their own songs and performs in public from time to time.

“The audience might expect us to sing songs that are kind of soft and caring, but actually we give them rock music on the stage. We don’t want to sell misery to people. We do this on purpose to fight against inherent prejudices.”

Wang Yi’ou (second from right) performs with her band

Wang Yi’ou (second from right) performs with her band

Wang, 39, with a height of 140 cm (4.5 feet), suffers from osteogenesis imperfect, a condition that causes extremely fragile bones, also known as “China doll” syndrome. She founded China-Doll Care and Support Association in 2007. After a decade committing to this social work, she created the Beijing-based Illness Challenge Foundation in 2016 to further advocate and provide support for people with all kinds of rare diseases.

Rare diseases have emerged on China’s public agenda in recent years. Though there’s still a lot to be done in this field compared with the U.S. and Europe, the fact that organizations like Wang’s are growing in size and influence reflects the country’s progress on addressing more and more needs of this vulnerable population.

 

 “Rare is many, rare is strong, rare is proud.”

Rare diseases are by definition very uncommon. In the US, a rare disease is defined as one that affects fewer than 200,000 people. The Europe Union sets the bar at one in 2,000, in Japan and Korea, it is one in 2,500.

When taken together, however, they are not rare at all. Behind these percentages are more than 350 million vivid lives – around 20 million in China alone according to incomplete statistics – who are suffering from over 7,000 varieties of rare diseases, with about 250 new diseases added to the list each year.

What is even rarer than the diseases themselves is their cures. Over 80% of rare diseases are genetic in origin, 50% begin in childhood, and so far only 5% have effective medicine and treatment. The journey of a patient and his/her family to obtain medical support is often difficult, complex, worrying and isolating.

Many ordinary people in China came to know rare diseases thanks to the world famous “Ice Bucket Challenge” in 2014. The splashy charity campaign for ALS was brought to China with the effort of Wang’s China-Doll Center for Rare Disorders . The campaign archived great success in drawing public attention to rare disease issues in the country.

Ice Bucket Challenge in China

Ice Bucket Challenge in China

Stephan Hawking was arguably the most well-known person to suffer from ALS in the world . In year 2020, another ALS patient in China walked into the lielight. Dr. Zhang Dingyu, president of Jiinyintan Hospital in Wuhan, a major battlefield for the fight against COVID-19, led 800 of his colleagues for months since the outbreak of COVID-19. The disease has begun to deprive Dr. Zhang of his leg strength. Watching him racing the clock with his hobbling steps making every effort to save people suffering from COVID-19, Chinese people witnessed  a noble, devoted and beloved man with a terrible and hateful rare disease.

Dr. Zhang Dingyu, president of Jinyintan Hospital in Wuhan

Dr. Zhang Dingyu, president of Jinyintan Hospital in Wuhan

 

The three key barriers

Increasing awareness of rare diseases is important because early intervention can greatly improve the rate of diagnosis and treatment. According to the latest U.S. National Organization for Rare Diseases 2019 survey, 50% of patients and caregivers attributed diagnostic delays to a lack of awareness. It is estimated that 40% of patients in the world have been misdiagnosed at least once, and it takes them more than five years on average to receive diagnosis.

Despite their great overall number, many rare disease patients are orphans of the health system. Limited medical specialization is part of the plight. Patients often face geographic barriers to get care. There are only a handful of specialists nationwide, or even worldwide, who have expertise in a given rare condition. As a result, patients often travel long distances to access their treating providers.

“There are fewer specialists available than rare disease patients,” pointed out Huifang Shang, deputy director of Department of Neurology, West China Hospital of Sichuan University at the 2020 China Conference on Rare Diseases. “Many rare diseases are not included in the medical school curriculum, and specialists need to accumulate experience in their real work, but if they practice in smaller hospitals, there are very few chances to gain experience in treating rare diseases.”

Treatment barriers are the second pain point. The issue of accessibility to live-saving drugs in China was highlighted in the 2018 blockbuster dramedy “Dying to Survive”. The film is based on a true story of a Chinese businessman who circumvented big pharmaceutical companies and illegally imported cheap generic medicine from India for leukemia patients. The man’s arrest sparked public outcry in the country and appears to have influenced government’s policies regarding approval for specific overseas medications to enter the market.

A film poster of “Dying to Survive”

A film poster of “Dying to Survive”

Given the fact that 95% of rare disease don’t actually have effective treatment to date, coordinated care and rehabilitation products and services are an even more pressing need for people affected by rare diseases.

Financial burden for patients is significant. Take Spinraza as an example. According to the report, the prescription medicine for spinal muscular atrophy (SMA) costs about US$ 750,000 dollars a year for patients in the U.S. and Europe, while with the favorable policies in China, SMA patients need to spend about RMB 1.05 million yuan(US$ 163,000) for a year of treatment. This is almost impossible for ordinary Chinese families, not to mention the cost of them in the process of seeking medical treatment, such as the expenses for transportation, accommodation and the loss of working time.

 

Maslow’s hierarchy of needs

Greater efforts are being made to address the “Maslow’s hierarchy of needs” for people with rare diseases in China during the past decade, from their need for diagnosis and treatment, to medical and financial support, and social participation.

Maslow's hierarchy of needs

A major milestone was the release of the country’s first list of rare diseases in May 2018, consolidating policy support for the R&D work of orphan drugs and treatment of 121 rare diseases which is estimated to be able to benefit about 3 million patients. By December 2020, China’s National Medical Products Administration has approved 95 medications for rare diseases on the list. The list and the drug approval process will continue to be improved in an accelerated speed.

With the policy in place, the question today has evolved from where treatments are to how to ensure patients can afford them. Addressing this aspect, business and social organizations can contribute more innovative solutions.

The internet helps to break some barriers. Through telemedicine, people with rare diseases have a much more convenient and efficient way to find doctors and drugs online, regardless of where they live. The internet can also promote doctor-to-doctor cross-disciplinary exchanges on their experiences of treating rare diseases. Last but not least, it provides an open platform for patients to communicate with each other, acquire healthcare knowledge and increase their sense of presence and social acceptance.

The Rare Disease Care Center is established with the goal to become an efficient platform with integrated treatment, medication, insurance and charity support for patients. JD Pharmacy is the drug-selling platform under JD Health. It provides the most comprehensive choices of oral medications for rare diseases available in China. The platform ensures to deliver authentic drugs via its proprietary logistics network, in many cases the cold chain network, to patient’s doorsteps in a secure and timely manner.

The platform will also strive to become a trusted and interactive place for doctors and patients to share their stories and experiences, not only addressing their medical needs, but also their emotional and life desires. “The aim of our Rare Disease Care Center is not only to help patients to address  the issues patients face in reality, but also to call on the society to give them more love and aid,” said Lijun Xin, CEO of JD Health.

“The issue of rare diseases is too complicated to be solved by any single party. It needs to be the shared responsibility of all of us in society,” said Wang Yi’ou, “The primary thing for our work is to influence people’s mindsets. People need to view us as a normal and also important part of society. Without such change of mindsets, even if all the policies are in place, rare diseases patients will still not be able to live a dignified life.”

Tagore also has following lines, “That which oppresses me, is it my soul trying to come out in the open, or the soul of the world knocking at my heart for its entrance?”

May human being conquer all rare diseases someday, when all the soul could come out in the open.

 

(Part one of two)

 

Read part two : In-Depth Report: To Make Solutions of Rare Diseases Not Rare

(vivian.yang@jd.com)

JD.com Named IFR Asia’s 2020 Issuer of the Year

by Vivian Yang

JD.com has been named the Issuer of the Year in IFR Asia’s 2020 Awards, as announced by the magazine on Feb 26, 2021. The awards are hosted by International Financing Review (IFR), a leading financial news magazine group headquartered in London.

JD.com has been named the Issuer of the Year in IFR Asia’s 2020 Awards

IFR said in an article on its website covering the news: “In a breakout year for Chinese technology stocks, one company delivered a series of popular and well-executed capital market deals. For raising its profile and winning over new followers, JD.com is IFR Asia’s Issuer of the Year.”

“JD.com completed an impressive range of capital markets financings in 2020, broadening its reach with global equity and debt investors and capitalising on a global shift to new-economy stocks,” the article continued.

In 2020, JD.com completed its secondary listing in Hong Kong on Jun. 18.  JD Health, the healthcare subsidiary JD.com also went public on HKEx six months later on Dec. 8.

The article also mentioned the IPOs of both JD Logistics, which filed its prospectus with HKEx earlier this month, and JD Technology is also on the way to go forward.

The magazine highlighted that JD’s resilience through the outbreak of COVID-19 is reflected in the company’s rise in credit quality, noting upgrades by both Moody’s and S&P.

“JD.com’s successes in 2020 sum up the adaptability that has been a hallmark since its earliest days. [Richard Liu, founder and CEO of JD.com] first turned to online sales in the aftermath of the SARS epidemic, launching electronics marketplace jdlaser.com in 2004. Sixteen years later, the coronavirus pandemic has again accelerated a shift in its business model – and transformed its profile in the capital markets,” said the article.

 

(vivian.yang@jd.com )

 

 

“Hoarding Clouds” Becomes a New Fashion of Chinese SMEs

by Vivian Yang

JD Cloud kicked off its spring promotion on Feb. 25, to offer cloud-based products and services at prices as low as 86% off. The promotion will last for a month until Mar. 31, coinciding with the prime time when small and medium enterprises plan their new year cloud deployment.

“Just like people hoard baby diapers, we are now hoarding the clouds,” said Qixiao Lin, a manager of a small retail company. “Now we can find good deals to prepare the resources.  I took in 5 times the public cloud resources as in the previous year during the promotion.”

Business demand for cloud resources are growing steadily on the Chinese market. For individuals and SMEs who do not have the ability and budget to build their private clouds, public cloud computing services are their ideal solutions.

Due to the outbreak of COVID-19, Yuanzhe Zhang’s online education company saw explosive growth in 2020 and their IT infrastructure under Zhang’s supervision underwent huge pressure overnight. Zhang was glad that the public cloud services he had prepared are highly flexible, helping him sail through this user surge. Zhang took advantage of the current promotion to book more than RMB 200,000-yuan worth of cloud resources in case of a rainy day in the future.

“Public clouds have become the water and electricity for the development of many SMEs,” said a representative of JD Cloud. “It will save them about 30% to make the purchase during the March promotion.”

JD Cloud provides cutting-edge scientific and technological capabilities in the fields of artificial intelligence, big data, cloud computing and the Internet of Things. Their ability has been repeatedly tested in China’s super shopping festivals, and can be customized to serve a variety of business needs.

 

(vivian.yang@jd.com)

Demand for Yuanxiao/Tangyuan Skyrockets ahead of the Lantern Festival

by Ella Kidron

Consumer preferences around Lantern Festival in China are changing, according to JD’s big data. Lantern Festival (which falls on the 15th day of the first month of the lunar calendar – Feb. 26 this year) is usually a time for people in China to gather around the table and eat “yuanxiao” in the north of China and “tangyuan” in the south of China. Both yuanxiao and tangyuan are glutinous rice balls which typically have a sweet filling.

JD big data shows that in the week leading up to the festival, the amount of glutinous rice balls sold increased eight times YOY, and lanterns doubled. This is no surprise as online channels have become a major force for the FMCG category, especially as of last year.

What is new, however, is the move towards new flavors and styles. For example, the sales volume of salty yolk-filled glutinous rice balls increased 1.5 times YOY. What’s more, among the fruit-flavored category, durian is the highest. Salty flavors are also highly popular, with fresh meat glutinous rice balls increasing by more than 1.5 times YOY. Consumers are also opting for lanterns which have creative designs on them.

In the week before Lantern festival, users searched most not for black sesame flavored glutinous rice balls (a traditional and popular flavor), but for rice rhubarb (大黄米), sugar-free, chocolate and other flavors. Lettuce sales also increased, thanks to the tradition in the south of China to consume it since the word for lettuce sounds like the word for “making money”(生财) in Chinese. Sales of lettuce increased by 77% YOY.

With the main New Year feasts of this year now over, consumers are looking to get back in shape. The sales volume of scales sold reached the highest level in nearly a month, while consumption of sports-related items increased more than 1.6 times YOY.

The below infographics indicate some of the Lantern Festival trends this year:

Popular products sold during Lantern Festival

Popular products sold during Lantern Festival

Popular flavors of glutinous rice balls include fresh meat, rhubarb rice, salty-yolk and sweet-scented osmanthus

Popular flavors of glutinous rice balls include fresh meat, rhubarb rice, salty-yolk and sweet-scented osmanthus

 

 

(ella@jd.com)

Photo Gallery: This Week at JD (Feb. 21 – Feb. 26)

JD CENTRAL (JDC) hosted the JD JOYFUL AWARDS on Feb. 25 at its headquarters in Bangkok and unveiled a new benchmark, “QPS”, to holistically evaluate merchants according to quality, price and service. The awards issued provide winning sellers with a wide range of supportive measures that go directly towards helping them improve their QPS rating.

 

JD Worldwide, JD.com’s imported products e-commerce platform, held its first online conference this year on Feb. 25 for potential partners and third-party companies, aiming to introduce more overseas brands to the platform. The online conference introduced the latest strategy of JD Worldwide and the new projects it is initiating to help overseas brands grow in China.

 

Kevin Jiang, president of international business, JD Fashion and Lifestyle, participated in a webinar hosted by the Chinese edition of WWD, and the British Fashion Council on Feb. 23 to discuss how the fashion industry is taking action to digitalize in the new normal. He introduced how JD helped brands and designers to deal with the impact of the pandemic, including omnichannel solutions, AR/VR technology, precise consumer targeting and more.

 

John Lobb, luxury shoes and boots brand from London under Hermès Group, launched a flagship store on JD.com on Feb. 23, which is the first and only e-commerce platform to partner with John Lobb in China.